Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin M Watts

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 2, 2017
Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemiaJennifer Chapman, Julia T Geyer, Mahsa Khanlari, et al.
Blood Neoplasia|June 2, 2025
Adult leukemia in Florida 2010-2019: diverse, aging population as an indicator for the United StatesMing S Lee, Rebecca E Kaiser, Christopher D Armstrong, et al.
Leukemia & Lymphoma|March 28, 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m<i>IDH1</i>) acute myeloid leukemia (AML)Jorge Cortes, Brian A Jonas, Gary Schiller, et al.
Cureus|June 28, 2021
Emergent Radiotherapy for Leukemia-Induced Cranial Neuropathies Refractory to Intrathecal TherapyNirav Patel, Benjamin J RIch, Shareen Patel, et al.
Leukemia Research|August 30, 2016
Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemiaJustin M Watts, Bogdan Dumitriu, Patrick Hilden, et al.
Blood Advances|July 16, 2025
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndromeJorge E Cortes, Jay Yang, Gail J Roboz, et al.
British Journal of Haematology|December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasmStéphane De Botton, Christian Récher, Jorge Cortes, et al.
British Journal of Haematology|June 27, 2015
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer CenterJustin M Watts, Ashwin Kishtagari, Meier Hsu, et al.
Leukemia Research|July 3, 2014
Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patientsJustin M Watts, Xin Victoria Wang, Mark R Litzow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2021
Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid MalignanciesMina M Tayari, Helena G Dos Santos, Deukwoo Kwon, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 2, 2017
Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemiaJennifer Chapman, Julia T Geyer, Mahsa Khanlari, et al.
Blood Neoplasia|June 2, 2025
Adult leukemia in Florida 2010-2019: diverse, aging population as an indicator for the United StatesMing S Lee, Rebecca E Kaiser, Christopher D Armstrong, et al.
Leukemia & Lymphoma|March 28, 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m<i>IDH1</i>) acute myeloid leukemia (AML)Jorge Cortes, Brian A Jonas, Gary Schiller, et al.
Cureus|June 28, 2021
Emergent Radiotherapy for Leukemia-Induced Cranial Neuropathies Refractory to Intrathecal TherapyNirav Patel, Benjamin J RIch, Shareen Patel, et al.
Leukemia Research|August 30, 2016
Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemiaJustin M Watts, Bogdan Dumitriu, Patrick Hilden, et al.
Blood Advances|July 16, 2025
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndromeJorge E Cortes, Jay Yang, Gail J Roboz, et al.
British Journal of Haematology|December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasmStéphane De Botton, Christian Récher, Jorge Cortes, et al.
British Journal of Haematology|June 27, 2015
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer CenterJustin M Watts, Ashwin Kishtagari, Meier Hsu, et al.
Leukemia Research|July 3, 2014
Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patientsJustin M Watts, Xin Victoria Wang, Mark R Litzow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2021
Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid MalignanciesMina M Tayari, Helena G Dos Santos, Deukwoo Kwon, et al.
Pageof 4